Planegg-Martinsried, Germany – Formycon AG (FSE: FYB,“Formycon”) today announces that the Brazilian regulatory authority ANVISA has granted marketing authorization for Ranivisio ®1, a ...

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) today announces that the Brazilian regulatory authority ANVISA has granted marketing authorization for Ranivisio ®1, a biosimilar to ...

A graduate of NU MOA achieved the highest score in the dental hygienists licensure examination held last month. According to the Professional Regulation Commission (PRC), 61 out of 73 test takers ...

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

Mangalore Refinery and Petrochemicals Ltd (MRPL) and Engineers India Ltd (EIL) have signed a memorandum of agreement (MoA) to accelerate growth in refining, petrochemicals, and renewable energy ...

Lucentis was first approved in the US in 2007 for wet AMD and grew quickly thereafter thanks to a string of additional indications, including DMO, myopic choroidal neovascularisation (mCNV) and ...

On Monday, the Minnesota Department of Health (MDH) said that two more cases of measles have been recorded, bringing the total to four cases so far this year. The additional cases come amid a ...

A Memorandum of Association (MOA) is a legal document prepared in the formation and registration process of a limited liability company to define its relationship with shareholders. The MOA is ...

MoA Clear Passage 2025 Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average ...

Elite two-way athlete Salesi Moa can exhale. After a whirlwind sequence last week which included official visits to Washington and Utah in the span of five days, the four-star prospect has time to ...

Germany’s Formycon (FSE: FYB) has announced that the Brazilian regulatory authority Anvisa has granted marketing authorization for FYB201/Ranivisio, a Lucentis (ranibizumab) biosimilar. The product ...

The products—ReoPro, Lucentis and Cimzia—are used as treatments for cardiovascular, ophthalmic and immunological indications, respectively (Table 1). All three approved products are Fab molecules.